Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease

Antimicrobial Agents and Chemotherapy
Bo Young LeeKyung-Wook Jo

Abstract

This study analyzed the recurrence rate and risk factors for recurrence of Mycobacterium avium complex (MAC) lung disease in patients successfully treated for this disease. The medical records of 158 patients successfully treated for MAC lung disease at a tertiary referral center in South Korea between March 2000 and December 2009 were retrospectively analyzed. Recurrence was recorded, and factors associated with recurrence were analyzed. The mean age of the 158 patients was 60.7 ± 11.1 years. The etiologic agent was Mycobacterium avium in 77 patients (48.7%) and Mycobacterium intracellulare in 81 patients (51.3%). Radiographic features included nodular bronchiectatic disease in 95 (60.1%), fibrocavitary disease in 49 (31.0%), and an unclassifiable form in 14 (8.9%) patients. Almost all (98.7%, 156/158) patients had been previously treated with a macrolide-containing regimen, and 68 (43.0%) patients had received treatment with an aminoglycoside. During a median follow-up of 43.8 months after completion of therapy, 50 patients (31.6%) experienced recurrence, at a median of 11.9 months after treatment completion. Multivariate analysis showed that only the nodular bronchiectatic form of the disease (hazard ratio, 2.39; 95% confide...Continue Reading

Citations

Mar 16, 2016·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Jason E StoutWing Wai Yew
Mar 12, 2016·Expert Review of Respiratory Medicine·Young Ae Kang, Won-Jung Koh
Nov 17, 2015·American Journal of Respiratory and Critical Care Medicine·Nasstasja Wassilew, Christoph Lange
Dec 25, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Won-Jung KohO Jung Kwon
Apr 4, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Takanori AsakuraMotofumi Ouchi
May 26, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sheng-Wei PanWei-Juin Su
Dec 6, 2017·Antimicrobial Agents and Chemotherapy·Byung Woo JhunWon-Jung Koh
Jul 18, 2018·Antimicrobial Agents and Chemotherapy·Byoung Soo KwonKyung-Wook Jo
May 3, 2016·Journal of Korean Medical Science·Yong-Soo Kwon, Won-Jung Koh
Jun 8, 2018·American Journal of Respiratory and Critical Care Medicine·Byung Woo JhunWon-Jung Koh
Oct 20, 2018·The European Respiratory Journal·Byoung Soo KwonKyung-Wook Jo
Nov 15, 2018·American Journal of Respiratory and Critical Care Medicine·Shelby Daniel-WaymanAdrian M Zelazny
Nov 6, 2018·General Thoracic and Cardiovascular Surgery·Katsuo YamadaKenji Ogawa
Sep 17, 2016·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Marc A BouffardNurhan Torun
Feb 27, 2020·Current Opinion in Pulmonary Medicine·Grant Waterer
Sep 22, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ock-Hwa KimKyung-Wook Jo
Jun 9, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Koji FuruuchiKozo Morimoto
Mar 23, 2017·Frontiers in Medicine·Yukiko NishiuchiFumito Maruyama
Dec 19, 2018·Frontiers in Microbiology·Colin SwensonKevin Fennelly
May 7, 2020·Journal of Clinical Medicine·Kiyoharu FukushimaHiroshi Kida
Mar 21, 2020·Frontiers in Immunology·Champa N RatnatungaJohn J Miles
Oct 3, 2017·Expert Review of Respiratory Medicine·Lars-Olof LarssonMichael R Loebinger
Jan 19, 2018·Current Opinion in Infectious Diseases·Leah LandeTheodore Plush
Mar 9, 2020·General Thoracic and Cardiovascular Surgery·Takuma YotsumotoHirotoshi Matsui
Feb 9, 2017·Cancer Control : Journal of the Moffitt Cancer Center·Aatif RashidJohn N Greene
Sep 2, 2020·International Journal of Molecular Sciences·Jigar P SethiyaElton Jeffrey North
Jul 15, 2021·Seminars in Respiratory and Critical Care Medicine·Shera Tan, Shannon Kasperbauer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Kyung-Wook JoTae Sun Shim
Respiration; International Review of Thoracic Diseases
S FujiuchiTetsuo Shimizu
American Journal of Respiratory and Critical Care Medicine
David E Griffith, Kevin L Winthrop
© 2022 Meta ULC. All rights reserved